 |
 |
 |
 |
NewsJanuary 9th, 2012Xenon to Collaborate with Genentech on Discovery of Novel Targeted Pain Therapeutics Vancouver, Canada (January 9, 2012) – Xenon Pharmaceuticals Inc. (Xenon) today announced a strategic alliance with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to... read more > January 6th, 2012 Xenon publishes new research papers Vancouver, Canada (Jan 6, 2012) – Xenon Pharmaceuticals Inc. (Xenon) authors publish new articles in Pain and Current Pharmaceutical Biotechnology. See PubMed for abstracts and links to full text.... read more > May 2nd, 2011 Xenon’s XEN402 Ointment Significantly Relieves Pain in Patients with Post Herpetic Neuralgia Vancouver, Canada (May 2, 2011) – Xenon Pharmaceuticals Inc. (Xenon) announced today that its novel ointment XEN402 demonstrated significant and clinically meaningful reductions in pain in patients with Post... read more > March 23rd, 2011 Xenon Chief Scientific Officer, Dr. Michael Hayden Receives Prestigious Award for Leadership in Medicine Vancouver, Canada (March 23rd, 2011) – Dr. Michael Hayden, a Xenon founder and Chief Scientific Officer, has received the Canada Gairdner Wightman Award for leadership in medical science in... read more > |